title: Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand.
abstract: Benign intracranial hypertension (BIH) is reported in three children from Australia and one from New Zealand, who were being treated with recombinant human growth hormone (rhGH). Three males and one female, aged between 10.5 and 14.2 y, developed intracranial hypertension within 2 weeks to 3 months of starting treatment. A national database, OZGROW, has been prospectively collecting data on all 3332 children treated with rhGH in Australia and New Zealand from January 1986 to 1996. The incidence of BIH in children treated with growth hormone (GH) is small, 1.2 per 1000 cases overall, but appears to be greater with biochemical GHD (<10 IU ml(-1)), i.e. 6.5/1000 (3 in 465 cases), relative risk 18.4, 95% confidence interval 1.9-176.1, than in all other children on the database. The incidence in patients with Turner's syndrome was 2.3/1000 (1 in 428 cases). No cases in patients with partial GHD (10-20 IU ml(-1)) or chronic renal failure were identified. Possible causative mechanisms are discussed. The authors' practice is now to start GH replacement at less than the usual recommended dose of 14 IU m(-2) week(-1) in those children considered to be at high risk of developing BIH. Ophthalmological evaluation is recommended for children before and during the first few months following commencement of rhGH therapy and is mandatory in the event of peripheral or facial oedema, persistent headaches, vomiting or visual symptoms. The absence of papilloedema does not exclude the diagnosis.
authors.affiliation: Department of Paediatric Endocrinology, John Hunter Children's Hospital, Newcastle, NSW, Australia.
authors.forename: P A
authors.initials: PA
authors.lastname: Crock
authors.forename: J D
authors.initials: JD
authors.lastname: McKenzie
authors.forename: A M
authors.initials: AM
authors.lastname: Nicoll
authors.forename: N J
authors.initials: NJ
authors.lastname: Howard
authors.forename: W
authors.initials: W
authors.lastname: Cutfield
authors.forename: L K
authors.initials: LK
authors.lastname: Shield
authors.forename: G
authors.initials: G
authors.lastname: Byrne
mesh_terms: D000293:Adolescent; D016907:Adverse Drug Reaction Reporting Systems; D001315:Australia / Q000453:epidemiology; D002648:Child; D005260:Female; D019382:Human Growth Hormone / Q000009:adverse effects*; D006801:Humans; D019586:Intracranial Hypertension / Q000139:chemically induced* / Q000453:epidemiology; D008297:Male; D009520:New Zealand / Q000453:epidemiology
chemical_list: D019382:Human Growth Hormone